RxDoctor Payments Data

Bruce Richman, DO

Family Medicine · Quakertown, PANPI 1609927441

Payments from drug & device makers

$19,215in general payments, 2019–2025

Across 1,080 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • Supernus Pharmaceuticals, Inc.$702
  • plus $10K from 54 others

What the payments were for

  • Travel & lodging$5863%
  • Food & beverage$18,50496%
  • Education$1261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)145$2,440
AstraZeneca119$2,042
Novo Nordisk93$1,609
Amgen97$1,304
Lilly USA, LLC56$1,031
Supernus Pharmaceuticals, Inc.38$702
Corcept Therapeutics39$670
Gilead1$586
Johnson & Johnson27$484
Bayer22$452
Astellas Pharma US Inc25$438
Boehringer Ingelheim20$401
Xeris Pharmaceuticals, Inc.23$387
Pfizer22$382
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)19$376
Sanofi-aventis U.S. LLC21$368
Almatica Pharma LLC20$367
Amarin Pharma, Inc.23$353
Bausch Health US, LLC18$328
GSK16$309
Teva Pharmaceuticals USA, Inc.16$308
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC18$279
Exact Sciences13$272
Novartis14$260
Esperion Therapeutics, Inc.13$227
Kowa Pharmaceuticals America, Inc.15$207
Otsuka America Pharmaceutical, Inc.9$201
Merck12$188
Evoke Pharma, Inc.9$161
Upsher-smith Laboratories LLC11$161
Tolmar, Inc.9$154
Lundbeck LLC7$147
Axsome Therapeutics, Inc.5$137
Eisai Inc.7$119
Amneal Pharmaceuticals LLC6$109
Dexcom, Inc.5$106
Viatris Specialty LLC6$98
Vertex3$93
Alkermes, Inc.5$88
Biodelivery Sciences International, Inc.4$64
Collegium Pharmaceutical, Inc.3$53
Circassia Inc.3$53
Inspire Medical Systems, Inc.2$49
Biohaven Pharmaceutical Holding Company Ltd.3$47
Vanda Pharmaceuticals Inc.3$47
Clarus Therapeutics Inc.3$47
Takeda Pharmaceuticals U.S.A., Inc.3$46
Verity Pharmaceuticals Inc.3$46
Biohaven Pharmaceuticals, Inc.3$42
Indivior Inc.2$40
Antares Pharma, Inc.2$39
Sunovion Pharmaceuticals Inc.3$35
Idorsia Pharmaceuticals US Inc2$35
Medtronic2$32
Daiichi Sankyo Inc.2$30
Medicure Pharma Inc.1$25
Adlon Therapeutics L.p.1$19
Abbott1$17
Intra-sana Laboratories1$17
E.r. Squibb & Sons, L.L.C.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,215 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$124,407
Medicare patients
206
Services billed
1,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide134$165,764
OzempicSemaglutide123$122,410
Cosentyx Sensoready (2 Pens)Secukinumab13$94,295
TrulicityDulaglutide50$48,678
VraylarCariprazine Hcl31$45,937
FarxigaDapagliflozin Propanediol38$42,871
EliquisApixaban49$38,685
JardianceEmpagliflozin38$35,350
NucyntaTapentadol Hcl12$27,353
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$18,865
XareltoRivaroxaban20$18,476
Spiriva RespimatTiotropium Bromide30$16,419
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl105$16,245
VascepaIcosapent Ethyl34$15,573
Repatha SureclickEvolocumab21$15,350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,031$214,443184 claims
Novo NordiskOzempic$1,609$122,410123 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat$401$57,83480 claims
AbbVieVraylar, Linzess, Synthroid$2,440$56,68691 claims
AstraZenecaFarxiga, Symbicort$2,042$49,52063 claims
PfizerEliquis$382$38,68549 claims
Collegium Pharmaceutical, Inc.Nucynta$53$27,35312 claims
GSKTrelegy Ellipta, Incruse Ellipta$309$25,90643 claims
Johnson & JohnsonXarelto$484$18,47620 claims
NovartisEntresto$260$7,44811 claims
Astellas Pharma US IncMyrbetriq$438$6,76811 claims
Indivior Inc.Suboxone$40$5,24513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Quakertown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →